HEALTHJul 1 · 11:38 UTCSTAT NEWSAdam Feuerstein

STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patients

The FDA approved Orca Bio's T cell therapy, Tregzi, which reduces immune reaction risks for blood cancer patients undergoing stem cell transplants. The therapy offers a curative alternative to traditional transplants that carry high risks of chronic graft-versus-host disease.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

FDAorganizationOrca BioorganizationTregziproductNate Fernhoffpersonblood cancertopicgraft-versus-host diseasetopicstem cell transplanttopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 18 · 10:30 UTC
Supercharging Immune Cells May Help Control HIV Long-Term
HEALTHApr 30 · 00:00 UTC
Long-lived immune cells show promise against cancer in world-first trial
HEALTHMay 30 · 10:05 UTC
NHS trial of blood test offers 'genuine hope' for people with some cancers
HEALTHMay 14 · 14:14 UTC
STAT+: BeOne wins FDA approval in lymphoma race
HEALTHMay 4 · 04:00 UTC
Thousands of cancer patients in England to benefit from new immunotherapy jab